BONESUPPORT Q1: A quarter cementing our thesis

Research Note

2021-05-06

13:56

Redeye’s optimistic view on the BONESUPPORT case remains following today’s report despite a slowdown in sales growth. We expect orthopaedic surgeries to accelerate significantly during H2, which, together with several exciting near-term catalysts, should fuel both its share price and revenue growth.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.